Cargando…

Gross tumor volume delineation in primary prostate cancer on (18)F-PSMA-1007 PET/MRI and (68)Ga-PSMA-11 PET/MRI

BACKGROUND: We aimed to assess the clinical value of (18)F-PSMA-1007 and (68)Ga-PSMA-11 PET/MRI in the gross tumor volume (GTV) delineation of radiotherapy for prostate cancer (PCa). METHODS: Sixty-nine patients were retrospectively enrolled (57 in the (18)F subgroup and 12 in the (68)Ga subgroup)....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yan-Nan, Lu, Zhen-Guo, Wang, Shuai-Dong, Lu, Xin, Zhu, Lei-Lei, Yang, Xu, Fu, Li-Ping, Zhao, Jun, Wang, Hai-Feng, Xiang, Zuo-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308314/
https://www.ncbi.nlm.nih.gov/pubmed/35869521
http://dx.doi.org/10.1186/s40644-022-00475-1
_version_ 1784752959426396160
author Zhang, Yan-Nan
Lu, Zhen-Guo
Wang, Shuai-Dong
Lu, Xin
Zhu, Lei-Lei
Yang, Xu
Fu, Li-Ping
Zhao, Jun
Wang, Hai-Feng
Xiang, Zuo-Lin
author_facet Zhang, Yan-Nan
Lu, Zhen-Guo
Wang, Shuai-Dong
Lu, Xin
Zhu, Lei-Lei
Yang, Xu
Fu, Li-Ping
Zhao, Jun
Wang, Hai-Feng
Xiang, Zuo-Lin
author_sort Zhang, Yan-Nan
collection PubMed
description BACKGROUND: We aimed to assess the clinical value of (18)F-PSMA-1007 and (68)Ga-PSMA-11 PET/MRI in the gross tumor volume (GTV) delineation of radiotherapy for prostate cancer (PCa). METHODS: Sixty-nine patients were retrospectively enrolled (57 in the (18)F subgroup and 12 in the (68)Ga subgroup). Three physicians delineated the GTV and tumor length by the visual method and threshold method with thresholds of 30%, 40%, 50%, and 60% SUVmax. The volume correlation and differences in GTVs were assessed. The dice similarity coefficient (DSC) was applied to estimate the spatial overlap between GTVs. For 51 patients undergoing radical prostatectomy, the tumor length (Lpath) of the maximum area was measured, and compared with the longest tumor length obtained based on the images (L(MRI), L(PET/MRI), L(PET), L(PET30%), L(PET40%), L(PET50%), L(PET60%)) to determine the best delineation method. RESULTS: In the (18)F subgroup, (1) GTV-PET/MRI (p < 0.001) was significantly different from the reference GTV-MRI. DSC between them was > 0.7. (2) GTV-MRI (R(2) = 0.462, p < 0.05) was the influencing factor of DSC. In the (68)Ga subgroup, (1) GTV-PET/MRI (p < 0.05) was significantly different from the reference GTV-MRI. DSC between them was > 0.7. (2) There was a significant correlation between GTV-MRI (r = 0.580, p < 0.05) and DSC. The longest tumor length measured by PET/MRI was in good agreement with that measured by histopathological analysis in both subgroups. CONCLUSION: It is feasible to visually delineate GTV on PSMA PET/MRI in PCa radiotherapy, and we emphasize the utility of PET/MRI fusion images in GTV delineation. In addition, the overlap degree was the highest between GTV-MRI and GTV-PET/MRI, and it increased with increasing volume.
format Online
Article
Text
id pubmed-9308314
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93083142022-07-24 Gross tumor volume delineation in primary prostate cancer on (18)F-PSMA-1007 PET/MRI and (68)Ga-PSMA-11 PET/MRI Zhang, Yan-Nan Lu, Zhen-Guo Wang, Shuai-Dong Lu, Xin Zhu, Lei-Lei Yang, Xu Fu, Li-Ping Zhao, Jun Wang, Hai-Feng Xiang, Zuo-Lin Cancer Imaging Research Article BACKGROUND: We aimed to assess the clinical value of (18)F-PSMA-1007 and (68)Ga-PSMA-11 PET/MRI in the gross tumor volume (GTV) delineation of radiotherapy for prostate cancer (PCa). METHODS: Sixty-nine patients were retrospectively enrolled (57 in the (18)F subgroup and 12 in the (68)Ga subgroup). Three physicians delineated the GTV and tumor length by the visual method and threshold method with thresholds of 30%, 40%, 50%, and 60% SUVmax. The volume correlation and differences in GTVs were assessed. The dice similarity coefficient (DSC) was applied to estimate the spatial overlap between GTVs. For 51 patients undergoing radical prostatectomy, the tumor length (Lpath) of the maximum area was measured, and compared with the longest tumor length obtained based on the images (L(MRI), L(PET/MRI), L(PET), L(PET30%), L(PET40%), L(PET50%), L(PET60%)) to determine the best delineation method. RESULTS: In the (18)F subgroup, (1) GTV-PET/MRI (p < 0.001) was significantly different from the reference GTV-MRI. DSC between them was > 0.7. (2) GTV-MRI (R(2) = 0.462, p < 0.05) was the influencing factor of DSC. In the (68)Ga subgroup, (1) GTV-PET/MRI (p < 0.05) was significantly different from the reference GTV-MRI. DSC between them was > 0.7. (2) There was a significant correlation between GTV-MRI (r = 0.580, p < 0.05) and DSC. The longest tumor length measured by PET/MRI was in good agreement with that measured by histopathological analysis in both subgroups. CONCLUSION: It is feasible to visually delineate GTV on PSMA PET/MRI in PCa radiotherapy, and we emphasize the utility of PET/MRI fusion images in GTV delineation. In addition, the overlap degree was the highest between GTV-MRI and GTV-PET/MRI, and it increased with increasing volume. BioMed Central 2022-07-22 /pmc/articles/PMC9308314/ /pubmed/35869521 http://dx.doi.org/10.1186/s40644-022-00475-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Zhang, Yan-Nan
Lu, Zhen-Guo
Wang, Shuai-Dong
Lu, Xin
Zhu, Lei-Lei
Yang, Xu
Fu, Li-Ping
Zhao, Jun
Wang, Hai-Feng
Xiang, Zuo-Lin
Gross tumor volume delineation in primary prostate cancer on (18)F-PSMA-1007 PET/MRI and (68)Ga-PSMA-11 PET/MRI
title Gross tumor volume delineation in primary prostate cancer on (18)F-PSMA-1007 PET/MRI and (68)Ga-PSMA-11 PET/MRI
title_full Gross tumor volume delineation in primary prostate cancer on (18)F-PSMA-1007 PET/MRI and (68)Ga-PSMA-11 PET/MRI
title_fullStr Gross tumor volume delineation in primary prostate cancer on (18)F-PSMA-1007 PET/MRI and (68)Ga-PSMA-11 PET/MRI
title_full_unstemmed Gross tumor volume delineation in primary prostate cancer on (18)F-PSMA-1007 PET/MRI and (68)Ga-PSMA-11 PET/MRI
title_short Gross tumor volume delineation in primary prostate cancer on (18)F-PSMA-1007 PET/MRI and (68)Ga-PSMA-11 PET/MRI
title_sort gross tumor volume delineation in primary prostate cancer on (18)f-psma-1007 pet/mri and (68)ga-psma-11 pet/mri
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308314/
https://www.ncbi.nlm.nih.gov/pubmed/35869521
http://dx.doi.org/10.1186/s40644-022-00475-1
work_keys_str_mv AT zhangyannan grosstumorvolumedelineationinprimaryprostatecanceron18fpsma1007petmriand68gapsma11petmri
AT luzhenguo grosstumorvolumedelineationinprimaryprostatecanceron18fpsma1007petmriand68gapsma11petmri
AT wangshuaidong grosstumorvolumedelineationinprimaryprostatecanceron18fpsma1007petmriand68gapsma11petmri
AT luxin grosstumorvolumedelineationinprimaryprostatecanceron18fpsma1007petmriand68gapsma11petmri
AT zhuleilei grosstumorvolumedelineationinprimaryprostatecanceron18fpsma1007petmriand68gapsma11petmri
AT yangxu grosstumorvolumedelineationinprimaryprostatecanceron18fpsma1007petmriand68gapsma11petmri
AT fuliping grosstumorvolumedelineationinprimaryprostatecanceron18fpsma1007petmriand68gapsma11petmri
AT zhaojun grosstumorvolumedelineationinprimaryprostatecanceron18fpsma1007petmriand68gapsma11petmri
AT wanghaifeng grosstumorvolumedelineationinprimaryprostatecanceron18fpsma1007petmriand68gapsma11petmri
AT xiangzuolin grosstumorvolumedelineationinprimaryprostatecanceron18fpsma1007petmriand68gapsma11petmri